RediCare Showcases Innovation in AI-Driven Chronic Disease Management at the 20th International Symposium on Atherosclerosis in Oman
On 6th December 2024, RediCare had the privilege of presenting at the 20th International Symposium on Atherosclerosis: Prevention of Cardiometabolic Diseases through Precision Medicine in Oman. The event brought together leading experts in cardiometabolic health to explore cutting-edge research and strategies for tackling chronic diseases globally.
Our Consultant Cardiologist and Clinical Advisor, Dr. Niall Colwell, delivered the presentation titled “Personalised AI-Delivered Lifestyle Intervention for Diabetes/Prediabetes in Primary Care.” The session provided an in-depth look at how RediCare’s evidence-based digital health solutions are transforming the management of chronic conditions in Primary Care.
Driving Innovation in Chronic Disease Management
Dr. Colwell highlighted RediCare’s role in advancing scalable, AI-driven approaches that seamlessly integrate with primary care workflows. The presentation emphasised the importance of tailored interventions for improving metabolic health outcomes, reducing demand on healthcare systems, and addressing health inequalities.
Foserting Global Collaboration
We were honoured to participate in this prestigious symposium, contributing to the global conversation on cardiometabolic disease prevention. These discussions are crucial for advancing population health through innovation and advancement in technology.
RediCare remains committed to transforming chronic disease management and prevention by combining cutting-edge AI, personalised lifestyle interventions, and seamless integration into healthcare systems. We thank the symposium organisers for this opportunity to share our vision and outcomes with the global medical community.
About RediCare
RediCare is a digital therapeutics firm. With our core product RediCare ControlDTx patients are transforming their health across the spectrum of metabolic health. They are experiencing clinically significant reductions in Weight, HbA1c, Blood Pressure and improved Lipid profiles and PCOS remission. Many Type 2 Diabetic patients have reduced and eliminated their diabetes medications.
RediCare ControlDTx is creating a new normal in prescription digital therapeutics for treating cardiometabolic diseases. We envision a new way to treat diseases like Type 2 diabetes and heart disease by targeting the root cause, not just the effects, using prescription digital therapeutics to deliver personalized clinically validated lifestyle therapy.
RediCare partners with primary care practices in the UK and Ireland and serves over 140 corporate clients with chronic disease screening and management services.